Analysts’ Recent Ratings Changes for Day One Biopharmaceuticals (DAWN)

Day One Biopharmaceuticals (NASDAQ: DAWN) has recently received a number of price target changes and ratings updates:

• 3/5/2025 – Day One Biopharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $39.00 to $34.00. They now have an “overweight” rating on the stock.
• 2/26/2025 – Day One Biopharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $32.00 price target on the stock.
• 2/26/2025 – Day One Biopharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
• 2/26/2025 – Day One Biopharmaceuticals had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a “buy” rating on the stock.
• 2/10/2025 – Day One Biopharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $48.00 to $43.00. They now have a “buy” rating on the stock.
• 1/13/2025 – Day One Biopharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $33.00 price target on the stock.
• 1/7/2025 – Day One Biopharmaceuticals had its price target lowered by analysts at Bank of America Co. from $28.00 to $25.00. They now have a “buy” rating on the stock.

Day One Biopharmaceuticals Stock Down 1.4 %

NASDAQ:DAWN traded down $0.12 during mid-day trading on Friday, hitting $8.98. 143,435 shares of the stock traded hands, compared to its average volume of 1,180,123. The business’s 50-day moving average price is $11.85 and its 200 day moving average price is $13.24. The company has a market cap of $909.76 million, a PE ratio of -8.71 and a beta of -1.38. Day One Biopharmaceuticals, Inc. has a 12-month low of $8.02 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million. Analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares in the company, valued at approximately $3,021,550.48. This represents a 1.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the sale, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,064 shares of company stock worth $651,225 in the last ninety days. 8.40% of the stock is currently owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in Day One Biopharmaceuticals during the fourth quarter worth about $27,000. R Squared Ltd bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $31,000. Quest Partners LLC raised its position in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after buying an additional 9,603 shares during the period. Finally, E Fund Management Co. Ltd. bought a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $143,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.